CLINICAL_TRIALS
trial_result
· 2021-04-02
Clinical Trial Update: Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial [Phase 3]
Summary
A phase 3 randomized trial evaluating cyproheptadine for severe COVID-19 has been unblinded but status is unknown.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ciusss de L'Est de l'Île de Montréal | Conditions: Viral Pneumonia, Serotonin Syndrome | Phase 3 | Status: UNKNOWN